Navigation Links
Edwards' CEO Invited To Address Congress On Opportunities To Revitalize Medical Device Innovation
Date:7/22/2014

WASHINGTON, July 22, 2014 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, announced that Edwards' Chairman and CEO Michael A. Mussallem today served as an expert panelist at the invitation of the United States Energy and Commerce Committee's Subcommittee on Health to discuss medical device innovation at its hearing, "21st Century Cures: Examining Barriers to Ongoing Evidence Development and Communication."

"Edwards has five decades of experience in developing and delivering new therapies to American patients, and we are concerned about the alarming and documented decline in U.S. medical innovation," said Mussallem.  "We identified areas of improvement that we believe can support a balanced ecosystem, which welcomes innovations to enable patients to live longer, healthier lives."

Mussallem noted the constructive and collaborative relationship with the Food and Drug Administration and the Centers for Medicare & Medicaid Services and identified three primary areas of improvement to promote America's leadership in medical device development, and ensure delivery of new treatments to patients around the world:

  • Evidence development mechanisms can be improved to reduce costs and delays.
  • Economic incentives need to be aligned with promoting innovation.
  • FDA's vision to improve the regulatory process must be accelerated.  

Mussallem drew on Edwards' experience with the SAPIEN transcatheter aortic heart valves to discuss the regulatory and reimbursement challenges and opportunities in the U.S.  His full written comments can be read at http://energycommerce.house.gov/hearing/barriers-ongoing-communication-and-evidence-development.  To learn more about the hearing or view a webcast of the event, visit the Energy and Commerce Committee's website at http://energycommerce.house.gov/studio/webcasts.

About Edwards Lifesciences
Edwards Lifesciences is the global leader in the science of heart valves and hemodynamic monitoring.  Driven by a passion to help patients, the company partners with clinicians to develop innovative technologies in the areas of structural heart disease and critical care monitoring, enabling them to save and enhance lives. Additional company information can be found at www.edwards.com

Edwards, Edwards Lifesciences, the stylized E logo and SAPIEN are trademarks of Edwards Lifesciences Corporation.  All other trademarks are the property of their respective owners.

Logo - http://photos.prnewswire.com/prnh/20140714/126903


'/>"/>
SOURCE Edwards Lifesciences Corporation
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Marshall Edwards Receives $4 Million Subscription From Novogen In Rights Offering
2. Novogen Board Approves US$4 Million Investment In Marshall Edwards Rights Offering
3. Marshall Edwards Announces First Cohort Of Patients Dosed In Phase I Clinical Trial Of Oncology Drug Candidate ME-344
4. Marshall Edwards Announces Name Change to MEI Pharma ("MEIP")
5. Edwards Lifesciences Chief Medical Officer to Keynote the Inaugural MedTech Cardio 2012 Conference at the MD&M Minneapolis Exposition and Conference
6. Updated: Harwood Feffer LLP Announces Investigation of Edwards Lifesciences Corporation
7. Acquisitions, Conference Participations, Court Rulings, and Product Deliveries - Research Report on Zoetis, Aegerion Pharmaceuticals, Edwards, Community Health Systems, and Air Methods
8. New Appointments, and Share Price Movements - Research Report on Humana, Illumina, Edwards Lifesciences, Aegerion Pharmaceuticals, and CytRx
9. RxAlly Member Pharmacies Invited To Become The Preferred Network For Smart Insurance Company Holdings, Inc.
10. NeuroSigma Invited to Present an Overview of eTNS for the Treatment of Epilepsy and Depression at The Royal Society of Medicine in London
11. PuraMed BioScience Invited to Discuss LipiGesic M on Armed Forces Network
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... SAN FRANCISCO, Calif. , June 24, 2016 ... GBT ), a biopharmaceutical company developing novel therapeutics ... significant unmet needs, today announced the closing of ... shares of common stock, at the public offering ... shares in the offering were offered by GBT. ...
(Date:6/24/2016)... , June 24, 2016 The Academy ... of recommendations that would allow biopharmaceutical companies ... with entities that make formulary and coverage decisions, a ... "value" of new medicines. The recommendations address ... not appear on the drug label, a prohibition that ...
(Date:6/24/2016)... , June 24, 2016 According ... by Type (Standard Pen Needles, Safety Pen Needles), Needle ... GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) - ... This report studies the market for the forecast period ... reach USD 2.81 Billion by 2021 from USD 1.65 ...
Breaking Medicine Technology:
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... Beach, CA (PRWEB) , ... June 25, 2016 , ... ... UCLA with Magna Cum Laude and his M.D from the David Geffen School of ... Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at the ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain ... for a minimum wage raise to $12 an hour by 2020 and then adjusting it ... the lost value of the minimum wage, assure the wage floor does not erode again, ...
Breaking Medicine News(10 mins):